PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
- P. Borchmann, H. Goergen, A. Engert
- MedicineThe Lancet
- 23 December 2017
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
- M. Fuchs, H. Goergen, A. Engert
- MedicineJournal of Clinical Oncology
- 10 September 2019
In early-stage favorable HL, a positive PET after two cycles ABVD indicates a high risk for treatment failure, particularly when a Deauville score of 4 is used as a cutoff for positivity in PET-2-positive patients.
Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma
- S. Theurich, S. Rothschild, M. Schlaak
- Medicine, BiologyCancer immunology research
- 27 July 2016
The data suggest that the addition of LPT to ipilimumab is safe and effective in patients with metastatic melanoma irrespective of clinical disease characteristics and known risk factors.
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
- P. Bröckelmann, H. Goergen, A. Engert
- MedicineJAMA Oncology
- 30 April 2020
Despite narrowly missing the efficacy benchmark in the concomitant group, the excellent 12-month progression-free survival and the unexpectedly high CR rate after 4 doses of nivolumab monotherapy warrant further evaluation of this approach in the first-line treatment of patients with early-stage cHL.
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label,…
- P. Borchmann, H. Haverkamp, A. Engert
- MedicineThe Lancet Oncology
- 1 April 2017
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.
- C. Kobe, H. Goergen, M. Dietlein
- MedicineBlood
- 22 November 2018
Residual uptake above that in the liver at PET-2 (ie, DS4) is an important risk factor regarding survival outcomes for patients treated with eBEACOPP upfront and is recommended as the cutoff value forPET-2 positivity.
Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
- D. Eichenauer, A. Plütschow, A. Engert
- MedicineJournal of Clinical Oncology
- 1 March 2020
The overall outcome of patients with NLPHL who had received Hodgkin lymphoma-directed first-line treatment in randomized GHSG trial protocols was good, Nonetheless, treatment optimization is still necessary to reduce toxicity in standard- risk patients and to improve the prognosis in high-risk patients.
Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer
- S. Temming, M. Kocher, S. Marnitz
- MedicineStrahlentherapie und Onkologie (Print)
- 1 February 2018
CyberKnife® lung SBRT which allows for real-time tumor tracking and risk-adapted fractionation achieves satisfactory local control and low toxicity rates in inoperable early-stage primary lung cancer patients.
Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma
- J. Mettler, H. Müller, C. Kobe
- MedicineJournal of Nuclear Medicine
- 7 June 2018
Baseline MTV as determined by different means is a predictive factor for early response to eBEACOPP after 2 cycles, however, value as a prognostic factor after a highly effective PET-2–adapted treatment strategy could not be observed.
...
...